All In Biotech

Drug Trial Radar · NCT07841093

A Study of JMKX003142 Tablet to Treat Renal Edema

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of JMKX003142 Tablet in the Treatment of Renal Edema

Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Feb 28, 2027

Primary completion

Apr 30, 2028

Study completion Jul 31, 2028

Sponsor

Lead sponsor
JemincareIndustry
Sponsor type
Industry
First posted
Sep 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy, safety, and of JMKX003142 administered randomly, double-blind, placebo-controlled study in Chinese renal edema patients with inadequate response to conventional diuretic therapy.

Conditions

  • Renal Edema
  • Nephrogenic Edema

Interventions

  • JMKX003142 TabletsDrug

    JMKX003142 tablets for experimental groups.Take the JMKX003142 tablets once daily(one hour after meals)for seven days.

  • Placebo TabletsDrug

    Placebo tablets for placebo group.Take the placebo tablets once daily (one hour after meals)for seven days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change of body weight from baselineTime frame: Day 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhejiang Hangyu Pharmaceutical Co., Ltd(subsidiary of Jemincare)

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.